Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
-- Collaboration joins together Xencor's modular XmAb engineered protein platforms with UCLA's expertise in biology to rapidly create and advance potential new medicines --
MONROVIA, Calif. & LOS ANGELES--February 25, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group (UCLA TDG), today announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencor's modular suite of XmAb® technology platforms. Xencor and UCLA have established a streamlined framework to select promising biology, perform collaborative research and license intellectual property.